SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.

Clinical trial NCT06835179 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06835179
Sponsor: The First Affiliated Hospital with Nanjing Medical University
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Unresectable Metastatic Colorectal Cancer Microsatellite Stable (MSS) Colorectal Cancer (CRC)RAS-mutant Colorectal Cancer

Start date: 2025-02-01
Primary completion: 2027-02-01
Enrollment: 28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.